Back to Peptide Index

FOXO4-DRI

LongevityEvidence Level: researchNot FDA-approved; extensive ongoing research suggests considerable promise for therapeutic applications in anti-aging medicine.
Peptide #12

FOXO4-DRI is a novel peptide designed specifically to target and eliminate senescent cells, playing a critical role in aging and age-related diseases. Derived from the FOXO4 protein, this peptide has attracted significant attention due to its potential for promoting healthy aging, improving tissue regeneration, and extending lifespan.

Alternative Names:

FOXO4 protein-derived peptide

Overview

FOXO4-DRI is a synthetic peptide specifically engineered to disrupt the interaction between the FOXO4 protein and the tumor suppressor protein p53 within senescent cells.

How It Works

FOXO4-DRI functions by selectively targeting senescent cells, disrupting FOXO4-p53 interactions, and triggering apoptosis to reduce the burden of senescent cells.

Clinical Effects

Improves organ function, enhances overall physical vitality, restores tissue homeostasis, extends lifespan, reduces chronic inflammation, and enhances tissue regeneration.

Therapeutic Applications

Anti-aging, tissue regeneration, combating degenerative conditions, chronic inflammatory diseases, and general age-related deterioration.

Research Studies

Clinical Trials

No comprehensive human clinical trials have been completed.

Preclinical Studies

Animal studies demonstrate improved organ function, enhanced physical vitality, restored tissue homeostasis, extended lifespan, and reduced inflammation.

Frequently Asked Questions

Is FOXO4-DRI legally available? Yes, for research purposes. Have human trials been conducted? No comprehensive trials yet. What are potential side effects? Minimal in preclinical studies. How is it administered? Subcutaneous or intraperitoneal injections. Can it be combined with other treatments? Interactions remain largely unexplored. Does it affect normal cells? Designed to target senescent cells selectively.

Quick Information

Safety Information

Safety Profile

Comprehensive safety, efficacy, and dosage guidelines remain undetermined.

Contraindications

Side Effects: Preclinical studies have shown minimal side effects, but long-term safety profiles require extensive further research. Safety Profile: Comprehensive safety, efficacy, and dosage guidelines remain undetermined.

Side Effects

Preclinical studies have shown minimal side effects, but long-term safety profiles require extensive further research.

Research References

Baar, M.P., et al. (2017). Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. Cell. Zhu, Y., et al. (2015). The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell. Kirkland, J.L., & Tchkonia, T. (2017). Cellular senescence: a translational perspective. EBioMedicine.

Additional Resources

View Source